Recurrent toxoplasmic retinochoroiditis - Significance of perilesional satellite dark dots seen by indocyanine green angiography

被引:13
作者
Bernasconi, O
Auer, C
Herbort, CP
机构
[1] LA SOURCE EYE CTR,CH-1004 LAUSANNE,SWITZERLAND
[2] UNIV LAUSANNE,HOP JULES GONIN,DEPT OPHTHALMOL,CH-1004 LAUSANNE,SWITZERLAND
关键词
indocyanine green angiography; toxoplasma retinochoroiditis; pyrimethamine; sulfadiazine;
D O I
10.3109/09273949709116896
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To suggest an explanation for the satellite dark dots seen by indocyanine green angiography (ICGA) around the main focus of a toxoplasmic retinochoroiditis. Methods: The authors analysed the evolution of ICG satellite dark dots in two cases of recurrent toxoplasmic retinochoroiditis receiving anti-toxoplasmic treatment not including corticosteroids. Results: Both patients had a recurrence on the peripheral aspect of scars from previous retinochoroiditis and were treated with pyrimethamine (50 mg/day) and sulfadiazine (4 g/day) for seven weeks. Resolution of satellite ICG dark dots was observed in both cases on the follow-up ICG angiogram performed at the end of treatment. Conclusion: Resolution of ICG satellite dark dots after anti-toxoplasmic treatment not including corticosteroids tends to indicate that there is probably an infectious component in these hypofluorescent dots and that they probably do not represent a purely inflammatory perilesional reaction.
引用
收藏
页码:207 / 211
页数:5
相关论文
共 4 条
[1]   Toxoplasmic retinochoroiditis: New insights provided by indocyanine green angiography [J].
Auer, C ;
Bernasconi, O ;
Herbort, CP .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1997, 123 (01) :131-133
[2]  
PAVESIO CEN, 1995, INVEST OPHTH VIS SCI, V36, P2166
[3]   THERAPY FOR OCULAR TOXOPLASMOSIS [J].
ROTHOVA, A ;
MEENKEN, C ;
BUITENHUIS, HJ ;
BRINKMAN, CJ ;
BAARSMA, GS ;
BOENTAN, TN ;
DEJONG, PTVM ;
KLAASSENBROEKEMA, N ;
SCHWEITZER, CMC ;
TIMMERMAN, Z ;
DEVRIES, J ;
ZAAL, MJW ;
KIJLSTRA, A .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1993, 115 (04) :517-523
[4]  
Tran V T, 1994, Ocul Immunol Inflamm, V2, P169, DOI 10.3109/09273949409057073